1 recruiting, 1 suspended. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Suspended 1 |
Follow Progressive Glioblastoma: new trials by email Literature Review of Progressive Glioblastoma trials Research Report on Progressive Glioblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography - Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Recruiting | Mayo Clinic | 36 | 2026-08-03 | 2026-10-30 |
| Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma Biopsy Procedure, Biospecimen Collection, Lomustine - Progressive Glioblastoma, Recurrent Glioblastoma | Phase 2 | Suspended | National Cancer Institute (NCI) | 184 | 2024-11-08 | 2026-11-03 |
Glioblastoma (2) · Astrocytoma (1) · Gliosarcoma (1)
Glioma (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Glandular and Epithelial (2) · Neoplasms, Nerve Tissue (2) · Neoplasms, Neuroepithelial (2) · Neuroectodermal Tumors (2) · Astrocytoma (1)
Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Surgical Procedures, Operative (2) · Biopsy (1) · Disulfides (1) · Immunoglobulin G (1) · Lomustine (1) · Nivolumab (1) · pembrolizumab (1) · relatlimab (1)
Mayo Clinic (1) · National Cancer Institute (NCI) (1)
United States (2)
Jian L Campian, MD, PhD (1) · Michael Lim (1)
U10CA180821 (1)